Presentation and talk with Craig Shimasaki, PhD, MBA, Cofounder & CEO, Moleculera Labs
In this presentation we will discuss biological, molecular, and clinical data explaining how molecular mimicry, through infections such as Strep, Lyme, and now SARS-CoV-2, can trigger immune dysregulation including autoantibodies directed against targets in the brain that interrupt normal neurologic functions.
Long-COVID is understood to be a condition where individuals experience a variety of neurologic, psychiatric, cardiovascular, and pulmonary symptoms many months after initially contracting the SARS-CoV-2 virus. Other post-infectious autoimmune syndromes may help us understand Long-COVID such as, persistent neurologic Lyme, Pediatric Acute Onset Neuropsychiatric Syndrome (PANS), Autoimmune Encephalopathy (AE), Basal Ganglia Encephalitis (BGE), and others.
Our understanding of Long-COVID is rapidly evolving. Infection-triggered autoimmune syndromes and molecular mimicry are medical model that may help us understand the pathophysiology of Long-COVD and lead to the integration of new diagnostics and more effective therapies to treat this rapidly expanding disorder.